JWJingjing Wu

Jingjing Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingjing Wu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Bixiang Zhang

    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Xiaoping Chen

    Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Abdoul-Aziz Mba'NBo-Koumpa

    Department of Hepatic Surgery Center, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

    1 shared publication
  • Bella Lingjia Liu

    Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA

    1 shared publication
  • Chang Shu

    Department of Hepatic Surgery Center, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

    1 shared publication
  • Chaoyi Yuan

    Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

    1 shared publication

Latest Publications

  • Open Access

    Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma

    by Yonglong Pan, Chenglong Zeng, Yi He, Ruizhi Chang, Jingjing Wu, Chaoyi Yuan, Haisen Li, Chen Su, Mengzhen Han, Pengcheng Li, et al.

    Protein kinases contribute to hepatocellular carcinoma (HCC) development and immune evasion, posing major challenges for HCC management. Here we show STE20/SPS1-related proline/alanine-rich kinase (SPAK) as a candidate immune exhaustion–associated gene identified through a pooled screen of protein kinases. By integrating bioinformatic analyses, data from patient cohorts, and functional studies in mouse models and cell lines, we demonstrate that elevated expression of SPAK promotes HCC progression, enhances stemness, drives immune exhaustion, and contributes to resistance to targeted therapies. Mechanistically, SPAK phosphorylates GSK3β at Ser9, thereby inhibiting proteasome-mediated degradation of c-Jun and PD-L1. Additionally, we find that DNMT3B-dependent intragenic methylation of SPAK contributes to its high expression in HCC. Notably, the SPAK inhibitor exhibits potent inhibitory effects and synergizes with PD-1 blockade to enhance antitumor efficacy. In summary, these findings establish SPAK as a driver of oncogenesis and immune exhaustion in HCC and highlight dual inhibition as a potential therapeutic strategy.


  • Open Access

    Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation

    by Jingjing Wu, Mingzhe Huang, Yuanhui Wu, Yisong Hong, Linbin Cai, Rongzhao He, Yanxin Luo, Puning Wang, Meijin Huang, Jinxin Lin

    Background: Neoadjuvant therapy followed by radical surgery is recommended for locally advanced rectal cancer (LARC). But radiotherapy can cause potential adverse effects. The therapeutic outcomes, postoperative survival and relapse rates between neoadjuvant chemotherapy (N-CT) and neoadjuvant chemoradiotherapy (N-CRT) patients have rarely been studied. Methods: From February 2012 to April 2015, patients with LARC who underwent N-CT or N-CRT followed by radical surgery at our center were included. Pathologic response, surgical outcomes, postoperative complications and survival outcomes (including overall survival [OS], disease-free survival [DFS], cancer-specific survival [CSS] and locoregional recurrence-free survival [LRFS]) were analyzed and compared. Concurrently, the Surveillance, Epidemiology, and End Results Program (SEER) database was used to compare OS in an external source. Results: A total of 256 patients were input into the propensity score-matching (PSM) analysis, and 104 pairs remained after PSM. After PSM, the baseline data were well matched and there was a significantly lower tumor regression grade (TRG) (P < 0.001), more postoperative complications (P = 0.009) (especially anastomotic fistula, P = 0.003) and a longer median hospital stay (P = 0.049) in the N-CRT group than in the N-CT group. No significant difference was observed in OS (P = 0.737), DFS (P = 0.580), CSS (P = 0.920) or LRFS (P = 0.086) between the N-CRT group and the N-CT group. In the SEER database, patients who received N-CT had similar OS in both TNM II (P = 0.315) and TNM III stages (P = 0.090) as those who received N-CRT. Conclusion: N-CT conferred similar survival benefits but caused fewer complications than N-CRT. Thus, it could be an alternative treatment of LARC.


  • Open Access

    Can probiotic supplements improve the symptoms of autism spectrum disorder in children?

    by Kai Feng, Ying Zhao, Qingyang Yu, Jialin Deng, Jingjing Wu, Lingjia Mm Liu

    Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with increasing incidence. The externalizing and internalizing problems among children with ASD often persistent and highly impair functioning of both the child and the family. Children with ASD often develop gut-related comorbidities and dysbiosis can have negative effects on not only the gastrointestinal (GI) tract, but also psychological symptoms. Dietary exclusions and probiotic supplements also have been investigated in the management of ASD symptoms. Especially, there is some anecdotal evidence that probiotics supplements are able to alleviate GI symptoms as well as improve behaviors in children with ASD. Method and analysis: This review will report on overall studies that include randomized control trials, randomized cross-over studies and cluster-randomized trials designs that consider curative effect in children with ASD by probiotic supplements. We will search 6 databases: MEDLINE, Embase, Scopus, PubMed, The Cochrane Library, and Web of Science and we will perform a manual search the journal Autism and information of ongoing or unpublished studies. The Mixed Methods Appraisal Tool (MMAT) will be used to assess quality of articles and the Jadad scale will be used to assess for bias. Assessment of publication bias will be performed using funnel plots generated by Comprehensive Meta-Analysis (CMA) 3.0 software. Clarifying the evidence in this area will be important for future research directions when reformulating and promoting the therapeutic regime in the field. Ethics and dissemination: There are no human participants, data, or tissue being directly studied for the purposes of the review; therefore, ethics approval and consent to participate are not applicable. The results of this study will be presented at conferences and published in peer-reviewed journals. Registration and status: PROSPERO 2019 CRD42019132754.


  • Open Access

    Dual Recombining-out System for Spatiotemporal Gene Expression in C. elegans

    by Ming-Hai Ge, Wei Wang, Tai-Hong Wu, Xin Wen, Umar Al-Sheikh, Li-Li Chen, Sheng-Wu Yin, Jing-Jing Wu, Jia-Hao Huang, Qing-Qin He, et al.


  • Open Access

    Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience

    by Jing-Jing Wu, Zhan-Guo Zhang, Peng Zhu, Abdoul-Aziz Mba'NBo-Koumpa, Bi-Xiang Zhang, Xiao-Ping Chen, Chang Shu, Wan-Guang Zhang, Ren-Jie Feng, Gan-Xun Li